Results for this period
Interim period (second quarter)1 September 2025–28 February 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Company-wide net sales declined because revenue from “Crash Fever” and “PANDOLAND” decreased year on year. While the Company continued upfront investment in the development of new titles and research and development, the decline in net sales resulted in a loss, and an impairment loss of ¥81.666 million on the operating rights for “Crash Fever” was recorded as an extraordinary loss.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 September 2025–28 February 2026 |
| Net Sales | ¥982 million (YoY -15.6%) |
| Operating profit | ¥-142 million |
| Ordinary income | ¥-154 million |
| Profit attributable to owners of the parent | ¥-261 million |
| Net income per share | -¥102.48 |
| Equity ratio | End of the current fiscal period 17.9 / End of previous period 30 |
| Total assets | ¥1,870 million |
| Net assets | ¥337 million |
| Cash flows from operating activities | ¥71,176 thousand |
| Cash flows from investing activities | ¥-9,707 thousand |
| Cash flows from financing activities | ¥138,580 thousand |
| Cash and cash equivalents at end of period | ¥1,455,235 thousand |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | ¥40,137 thousand |
| Impairment loss | ¥81,666 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Item Impairment Losses / Amount ¥81,666 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 2,598,212 Shares |
| Treasury Shares at Period-End | 48,656 Shares |
| Factors Behind Changes in Business Performance | Company-wide net sales declined because revenue from “Crash Fever” and “PANDOLAND” decreased year on year. While the Company continued upfront investment in the development of new titles and research and development, the decline in net sales resulted in a loss, and an impairment loss of ¥81.666 million on the operating rights for “Crash Fever” was recorded as an extraordinary loss. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Company-wide net sales declined because revenue from “Crash Fever” and “PANDOLAND” decreased. Amid continued upfront investment in the development of new titles and ongoing research and development, the decline in revenue resulted in operating and ordinary losses, while the impairment loss on the operating rights for “Crash Fever” further reduced interim net income.